Practical Management Options for Alcohol Dependence, Part 3 of 3 - Initiating Pharmacotherapy in Patients with Alcohol Dependence
neuroscienceCME Clinical Navigator
Premiere Date: Wednesday, December 19, 2007This activity offers CE credit for:
- Physicians (ACCME/AMA PRA Category 1)
- Nurses (CNE)
- Pharmacists (ACPE)
- Psychologists (APA)
- Social Workers (NASW)
- Certified Case Managers (CCMC)
- Addiction Professionals (NAADAC)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Friday, December 19, 2008
Note: Credit Is No Longer Available
 | Kyle M. Kampman, MD Associate Professor, Department of Psychiatry University of Pennsylvania School of Medicine Medical Director, University of Pennsylvania Treatment Research Center Medical Director, Charles O'Brien Center for the Treatment of Addictions Philadelphia, PA |
The treatment goal for alcohol dependence is to increase rates of
abstinence. When used in combination with psychosocial support,
pharmacologic agents can help committed patients reach this goal.
The NIAAA notes that all FDA-approved drugs have been shown
to be effective adjuncts to the treatment of alcohol dependence
and should be considered for patients with active alcohol
dependence or for patients who have relapsed. Patients who have
previously failed to respond to psychosocial approaches alone
are particularly strong candidates. Physicians continue to struggle
with the effective management for this patient population. In this
neuroscienceCME Clinical Navigator series, experts will address
these issues and give clinicians tools that they can utilize in their
practice to improve the outcomes of their patients with alcohol
dependence.
- American Psychiatric Association. Understanding Alcohol Use Disorders and Their Treatment, 2001.
- NIAAA. Helping patients who drink too much: NIH Government Publications; 2005. Available at: http://www.niaaa.nih.gov/Publications/EducationTrainingMaterials/guide.htm. Accessed October 11, 2007.
To examine the pivotal role of the biopsychosocial evaluation in the treatment of alcohol dependence with psychosocial interventions and FDA-approved pharmacotherapy; and to recognize and evaluate common treatment issues that can be associated with pharmacotherapy in patients with alcohol dependence.
At the end of this CE activity, participants should be able to:
- Describe important aspects of the biopsychosocial evaluation of alcohol dependence.
- Analyze how to individualize pharmacotherapy for patients with alcohol dependence.
- Recognize and evaluate common treatment issues that can be associated with pharmacotherapy in patients with alcohol dependence.
CME Outfitters, LLC, gratefully acknowledges an independent educational grant from Cephalon, Inc., and Alkermes, Inc., in support of this CE activity.
Physicians, physician assistants, nurse practitioners, nurses, psychologists, social workers, certified case managers, pharmacists, and other healthcare professionals with an interest in alcohol dependence.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education to
provide continuing medical education for physicians.
CME Outfitters, LLC, designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.
Physicians should only claim credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
CME Outfitters, LLC, is an approved provider of continuing nursing education by the New York State Nurses
Association, which is accredited as an approver of continuing nursing education by the American Nurses Credentialing
Center’s Commission on Accreditation.
It has been assigned code 6WASUP-PRV-0625. 1.0 contact hour (Pharmacology)
Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.
CEP Credit (Psychologists):
CME Outfitters is approved by the American Psychological Association to sponsor continuing education for
psychologists.
CME Outfitters maintains responsibility for this program and its content. (1.0 CE credits)
NASW Credit (Social Workers):
This program was approved by the National Association of Social Workers (provider #886407722) for 1 continuing
education contact hour.
CCMC Credit (Certified Case Managers):
This program has been approved for 1 hour by the Commission for Case Manager Certification (CCMC).
NAADAC Credit (Addiction Professionals):
CME Outfitters, LLC, is an approved education provider by NAADAC, the Association for Addiction
Professionals. Provider Number 636. This activity is designated for 1.0 contact hour.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of
continuing pharmacy education. 1.0 contact hours (0.1 CEUs)
Universal Program Number: 376-000-07-025-H01-P
Credit Instructions/Requirements
Successful completion of this CE activity includes reviewing the course materials in their entirety, and following the appropriate set of instructions below:
Option A:
To complete your credit request form, activity evaluation, and post-test online (70% pass rate required), and print your certificate or statement of credit immediately, please visit www.neuroscienceCME.com and click on the Testing/Certification link under the Resources tab (requires free account activation).
Option B:
- If you do not have Internet access and require hard copies of the post-test, credit request form and evaluation, please call 877.CME.PROS to receive copies via e-mail, fax, or postal mail.
- Complete the credit request form and activity evaluation. Successfully complete the post-test and record your responses on the credit request form.
- Submit completed forms via FAX to 240.243.1033 or mail to:
CME Outfitters, LLC
2400 Research Boulevard, Suite 425
Rockville, MD 20850
Attention: CE Forms Processor - Participants will receive a certificate or statement of credit within 4-6 weeks following receipt of the credit request form and activity evaluation form.
Kyle M. Kampman, MD
A board-certified psychiatrist specializing in addiction psychiatry, Dr. Kampman received his medical degree from Tulane
University School of Medicine. He interned at the National Naval Medical Center in Bethesda, Maryland, and served as a general
medical officer in the Navy until 1990. He completed his residency in psychiatry and fellowship in addiction psychiatry at the
University of Pennsylvania.
Currently, Dr. Kampman is Medical Director of the Charles O’Brien Center for the Treatment of Addictions, Associate Professor of
Psychiatry, and Medical Director of the Treatment Research Center at the University of Pennsylvania in Philadelphia. His research
interests include pharmacotherapy for cocaine dependence and cocaine withdrawal syndrome.
Dr. Kampman and his colleagues at the Treatment Research Center developed a scale that measures cocaine withdrawal
symptom severity, the Cocaine Selective Severity Assessment (CSSA). He has written several papers showing that cocaine
withdrawal symptom severity, measured by this scale, can predict outcome in cocaine dependence treatment. He has also used
this scale to identify a subgroup of cocaine-dependent patients who appear to respond well to medications aimed at reducing
cocaine withdrawal symptoms such as amantadine and propranolol.
Dr. Kampman recently completed a successful pilot trial of topiramate for relapse prevention in the treatment of cocaine
dependence. Based on the positive results of the pilot study and results from the University of Texas showing topiramate’s
efficacy for the treatment alcohol dependence, Dr. Kampman received a grant from NIAAA funding a study of topiramate for
alcoholism and comorbid cocaine dependence.
Dr. Kampman currently serves on the editorial board of the Journal of Addiction Medicine and is an active member of the
American Society of Addiction Medicine, College on Problems of Drug Dependence, and the Pennsylvania Society of Addiction
Medicine. His contributions to the field have been acknowledged by the Scott Mackler Award for Excellence in Substance Abuse
Teaching presented by the University of Pennsylvania School of Medicine and the Caron Foundation’s Medical Professional-
Physician Award.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all its CE
activities. Faculty must disclose to the participants any significant relationships with commercial companies whose products or
devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has
evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure,
use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant
information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Kampman has disclosed that he receives grants from Alkermes, Inc. He is also on the speakers bureaus of Cephalon, Inc., Forest
Pharmaceuticals, Inc., and Reckitt Benckiser PLC.
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The
faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational
uses (any uses not approved by the FDA) of products or devices.
CME Outfitters, LLC, the faculty, Cephalon, Inc., and Alkermes, Inc., do not endorse the use of any product outside of the FDA
labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during
this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
CN-019-121907-15
